Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea

DuPont, Hurbert L., MD

Status and phase

Completed

Phase 2

Conditions

Diarrhea

Treatments

Drug: rifaximin

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00098384

PR 03

Details and patient eligibility

About

The purpose of this study is to evaluate the effectiveness of poorly absorbed rifaximin in the prevention of travelers' diarrhea among U.S. college students in Mexico for five weeks.

Full description

This is an investigator-initiated proposal wherein 220 male and female subjects >17 years of age from industrialized regions were randomized to receive a poorly absorbed antibiotic, rifaximin, in one of three doses at mealtime (when they are exposed to diarrhea-causing bacteria), 200 mg once a day, 200 mg twice a day or 200 mg three times a day versus a placebo starting on arrival (within the first 72 hours) to Mexico and continuing for two weeks with diaries of symptoms recorded for three weeks. Adverse events in the subjects were followed for five weeks. If mild diarrhea (1 or 2 unformed stools/24 hours plus an enteric symptom) or diarrheal illness (>2 unformed stools/24 hours plus an enteric symptom) developed, subjects provided a stool sample to determine cause of illness. Forty subjects provided stool samples after 7 days and 14 days treatment to see if their intestinal bacterial flora had developed resistance to rifaximin and to see the level of drug achieved. Stool samples from these forty subjects were studied for enteric pathogens to look for asymptomatic infection during the period of prophylaxis. The stool samples collected were initially processed in our enteric laboratories in Guadalajara, Mexico. Specialized tests such as studies of toxigenicity for enterotoxigenic E. coli and enteroadherence for enteroaggregative E. coli were done in Houston.

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

An Investigational Review Board approved, written informed consent is appropriately witnessed, signed and dated prior to any study-related activities
Male or female subjects 18 years of age or older
Able to read and understand English
Enrolled and started on prophylaxis within 72 hours of arrival in Mexico
If the subject is female, only women with non-childbearing potential or those who are not pregnant will be eligible. Urine pregnancy tests will be performed on those women who question their pregnancy status. Women on the study are required to employ a reliable method of contraception while taking medication. Forms of acceptable contraception include:
- Double barrier method of contraception.
- Oral birth control pills for at least two cycles before enrollment and continuing during therapy - subjects will be told they should use a barrier contraception method during the study as well.
- Norplant inserted at least one month before enrollment.
- An intrauterine device inserted by a qualified clinician.
- Medroxyprogesterone acetate for a minimum of one month before study and administered for one month following study completion.
- An approved birth control patch for at least two cycles before enrollment and continuing during therapy. OR
- Complete abstinence from intercourse for the two weeks of medication.

Exclusion criteria

Acute diarrhea (criteria for travelers' diarrhea above) within the past week
Diarrhea developing within 24 hours of study enrollment
In Mexico for more than 72 hours
Receipt of one of the following classes of drugs: fluoroquinolone (any drug in class), macrolide or azalide or trimethoprim-sulfamethoxazole within the past week or during the three week study
Receipt of other medication to decrease the occurrence of diarrhea (e.g. bismuth subsalicylate or lactobacillus preparations)
For females, pregnancy or breast feeding during the three week study
Receipt of antidiarrheal medication (loperamide, bismuth subsalicylate, kaopectate) within 24 hours of enrollment
Hypersensitivity to rifaximin
Unstable medical condition including chronic renal failure and insulin dependent diabetes.